Quick Takeaways
- JPMORGAN CHASE & CO filed SCHEDULE 13G/A for REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN).
- Disclosed ownership: 4.4%.
- Date of event: 30 May 2025.
JPMORGAN CHASE & CO - 30 May 2025 SCHEDULE 13G/A Report for REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN)
- Filing Manager
- JPMORGAN CHASE & CO
- Reporting Manager
- JPMORGAN CHASE & CO.
- Symbol
- REGN
- Shares outstanding
- 107,786,614 shares
- Disclosed Ownership
- 4,742,611 shares
- Ownership
- 4.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 05 Jun 2025, 11:11:31 UTC
- Date of event
- 30 May 2025
- Previous filing
- 22 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JPMORGAN CHASE & CO disclosed 4.4% ownership in REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN) on 30 May 2025."
What Changed
- Previous schedule filing date: 22 Apr 2025.
- Current filing was accepted on 05 Jun 2025, 11:11.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO. | 4.4% | 4,742,611 | 4,189,434 | 41,470 | Rachel Tsvaygoft | Vice President |